Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1855 1
1867 2
1872 1
1946 1
1950 1
1951 1
1952 3
1953 1
1954 3
1956 1
1957 1
1958 4
1959 2
1960 5
1961 3
1962 3
1963 5
1964 12
1965 11
1966 5
1967 12
1968 7
1969 12
1970 17
1971 15
1972 13
1973 14
1974 4
1975 8
1976 2
1977 6
1978 3
1979 21
1980 20
1981 19
1982 10
1983 13
1984 18
1985 23
1986 11
1987 11
1988 9
1989 13
1990 12
1991 14
1992 20
1993 18
1994 14
1995 8
1996 12
1997 10
1998 17
1999 13
2000 13
2001 17
2002 14
2003 13
2004 16
2005 17
2006 33
2007 35
2008 21
2009 36
2010 35
2011 42
2012 49
2013 40
2014 49
2015 62
2016 70
2017 61
2018 91
2019 101
2020 99
2021 81
2022 101
2023 85
2024 79
2025 98
2026 66

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,714 results

Results by year

Filters applied: . Clear all
Page 1
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: hammond d. Leukemia. 2025 Apr;39(4):854-863. doi: 10.1038/s41375-025-02531-8. Epub 2025 Feb 25. Leukemia. 2025. PMID: 40000842 Free PMC article. Clinical Trial.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Bataller A, et al. Among authors: hammond d. Am J Hematol. 2023 Nov;98(11):1780-1790. doi: 10.1002/ajh.27070. Epub 2023 Sep 4. Am J Hematol. 2023. PMID: 37665752 Free PMC article.
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: hammond de. J Clin Oncol. 2025 Aug 20;43(24):2692-2699. doi: 10.1200/JCO-25-00640. Epub 2025 Jun 13. J Clin Oncol. 2025. PMID: 40513054 Free PMC article.
Clonal haematopoiesis of emerging significance.
Hammond D, Loghavi S. Hammond D, et al. Pathology. 2021 Apr;53(3):300-311. doi: 10.1016/j.pathol.2021.02.005. Epub 2021 Mar 6. Pathology. 2021. PMID: 33685721 Review.
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.
Bazinet A, Loghavi S, Wei Y, Bataller A, Sasaki K, Arani N, Darbaniyan F, Chien K, Hammond D, Bouligny I, Kanagal-Shamanna R, Thongon N, Tang G, Urrutia S, Kadia T, DiNardo C, Daver N, Short N, Issa G, Pemmaraju N, Jabbour E, Wang SA, Wang W, Borthakur G, Bueso-Ramos C, Ravandi F, Medeiros LJ, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Bazinet A, et al. Among authors: hammond d. Leukemia. 2025 Sep;39(9):2256-2265. doi: 10.1038/s41375-025-02711-6. Epub 2025 Jul 21. Leukemia. 2025. PMID: 40691503
Germline Predisposition to Myelodysplastic Syndromes.
Gener-Ricos G, Gerstein YS, Hammond D, DiNardo CD. Gener-Ricos G, et al. Among authors: hammond d. Cancer J. 2023 May-Jun 01;29(3):143-151. doi: 10.1097/PPO.0000000000000660. Cancer J. 2023. PMID: 37195770
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.
Montalban-Bravo G, Loghavi S, Li Z, Chien K, Kanagal-Shamanna R, Bataller A, Natu A, Gurney M, Bazinet A, Hammond D, Sasaki K, Borthakur G, Swaminathan M, DiNardo C, Kadia T, Ravandi F, Daver N, Short N, Pemmaraju N, Issa G, Lasho TL, Finke CM, Al-Kali A, Csizmar C, Alkhateeb H, Gangat N, Mangaonkar AA, Bueso-Ramos C, Tefferi A, Kantarjian H, Garcia-Manero G, Patnaik MM. Montalban-Bravo G, et al. Among authors: hammond d. Blood Adv. 2025 Oct 14;9(19):5105-5117. doi: 10.1182/bloodadvances.2025016529. Blood Adv. 2025. PMID: 40644618 Free PMC article.
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.
Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Croden J, et al. Among authors: hammond d. Leukemia. 2025 Oct;39(10):2538-2541. doi: 10.1038/s41375-025-02733-0. Epub 2025 Aug 14. Leukemia. 2025. PMID: 40813623 Free PMC article. No abstract available.
1,714 results